期刊文献+

肝细胞癌伴Ⅳ型门静脉癌栓患者经局部及靶向治疗完全缓解1例

A case of complete remission of hepatocellular carcinoma with type portal vein tumor thrombus by local and targeted therapy
下载PDF
导出
摘要 肝细胞癌(hepatocellular carcinoma,HCC)合并门静脉癌栓(portal vein tumor thrombus,PVTT),尤其是Ⅳ型癌栓者难治疗、预后差。本文报道1例初诊确诊为HCC合并Ⅲ型PVTT患者,经肝动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)1次+射频消融治疗(radiofrequency ablation,RFA)1次+索拉非尼(400 mg,每日2次)治疗1个月后进展为HCC合并Ⅳ型癌栓,经乐伐替尼(12 mg,每日1次)治疗1个月达肿瘤降期,再次联合TACE治疗1次+RFA治疗1次,肿瘤评估完全缓解(complete remission,CR)。 Patients of hepatocellular carcinoma(HCC)with portal vein tumor thrombus(PVTT),especially those with type Ⅳ PVTT were difficult to treat and the prognosis was poor.This paper reported a newly diagnosed case of HCC with type Ⅲ PVTT,who was treated by transcatheter arterial chemoembolization(TACE)one time + radiofrequency ablation(RFA)one time + sorafenib(400 mg,twice per day)for one month,then the case progressed to type Ⅳ PVTT and received lenvatinib(12 mg,once per day)for one month,and the stage of tumor descended.The patient received TACE(one time)+ RFA(one time)again,and the tumor assessment reached complete remission(CR).
作者 张海娇 刘晓民 孙巍 魏建莹 陈京龙 ZHANG Hai-jiao;LIU Xiao-min;SUN Wei;WEI Jian-ying;CHEN Jing-long(Center of Internal Medicine Oncology,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China)
出处 《中国肝脏病杂志(电子版)》 CAS 2019年第1期85-89,共5页 Chinese Journal of Liver Diseases:Electronic Version
基金 首都临床特色应用研究与成果推广(Z161100000516141)
关键词 肝细胞癌 局部治疗 索拉非尼 乐伐替尼 Hepatocellular carcinoma Locoregional therapy Sorafenib Lenvatinib
  • 相关文献

参考文献9

二级参考文献48

  • 1李敬东,曾勇,李波,卢实春,严律南.肝癌伴胆管癌栓致梗阻性黄疸的诊断和治疗[J].中华肝胆外科杂志,2004,10(1):60-61. 被引量:5
  • 2JiaFan JianZhou Zhi-QuanWu Shuang-JianQiu Xiao-YingWang Ying-HongShi Zhao-YouTang.Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis[J].World Journal of Gastroenterology,2005,11(8):1215-1219. 被引量:65
  • 3Jemal AI, Bray F, Center MM, et al. Global cancer statistics[J].CA Cancer J Clin, 2011,61 (2):69-90.
  • 4Llovet JM,Bruix J. Molecular targeted therapies in hepatocellular carcinoma[J]. Hepatology, 2008,48(4):1312-1327.
  • 5Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hep- atocellular carcinoma[J]. N Engl J Med, 2008,359(4):378-390.
  • 6Cheng AL, Kang YK, Chen Z, et al. Efficacy and s~ety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase I~ randomised, double-blind, placebo-con- trolled trial[J]. Lancet Oncol, 2009,10(1):25-34.
  • 7Welker MW, Lubomierski N, Gog C, et al. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions[J]. J Chemother, 2010,22 ( 3 ) :205-211.
  • 8Leneioni R, Kudn M, Ye SL, et al. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hcpatn- cellular carcinoma and of its treatment with sorafeNib) non-inter- ventional study[J]. lnt J Clin Praet, 2012,66(7):675-683.
  • 9Lencioni R, Kudo M, Ye SL, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis[J], lnt J Clin Pract, 2014,68(5):609-617.
  • 10Mizandari M,Ao G,Zhang Y,et al.Novel Percutaneous radiofrequency ablation of portal vein tumor thrombus: safety and feasibility.Cardiovasc Intervent Radiol,2014,35:104-110.

共引文献975

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部